1. A phase I first‐in‐human study with tefinostat – a monocyte/macrophage targeted histone deacetylase inhibitor – in patients with advanced haematological malignancies. (7th May 2013) Authors: Ossenkoppele, Gert J.; Lowenberg, Bob; Zachee, Pierre; Vey, Norbert; Breems, Dimitri; Van de, Arjan A.; Davidson, Alan H.; Wells, Graham; Needham, Lindsey; Bawden, Lindsay; Toal, Martin; Hooftman, Leon; Debnam, Phillip M. Journal: British journal of haematology Issue: Volume 162:Number 2(2013:Jul.) Page Start: 191 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Changes in quality of life and disease‐related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy. (3rd January 2016) Authors: Mesa, Ruben; Verstovsek, Srdan; Kiladjian, Jean‐Jacques; Griesshammer, Martin; Masszi, Tamas; Durrant, Simon; Passamonti, Francesco; Harrison, Claire N.; Pane, Fabrizio; Zachee, Pierre; Zhen, Huiling; Jones, Mark M.; Parasuraman, Shreekant; Li, Jingjin; Côté, Isabelle; Habr, Dany; Vannucchi, Ales... Journal: European journal of haematology Issue: Volume 97:Number 2(2016:Aug.) Page Start: 192 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide. (17th May 2017) Authors: Harrison, Claire N.; Griesshammer, Martin; Miller, Carole; Masszi, Tamas; Passamonti, Francesco; Zachee, Pierre; Durrant, Simon; Pane, Fabrizio; Guglielmelli, Paola; Verstovsek, Srdan; Jones, Mark M.; Hunter, Deborah S.; Sun, William; Li, Jingjin; Khan, Mahmudul; Habr, Dany; Kiladjian, Jean‐Jacques Journal: British journal of haematology Issue: Volume 182:Number 2(2018) Page Start: 279 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Issue 7 (July 2017) Authors: Harrison, Claire N; Schaap, Nicolaas; Vannucchi, Alessandro M; Kiladjian, Jean-Jacques; Tiu, Ramon V; Zachee, Pierre; Jourdan, Eric; Winton, Elliott; Silver, Richard T; Schouten, Harry C; Passamonti, Francesco; Zweegman, Sonja; Talpaz, Moshe; Lager, Joanne; Shun, Zhenming; Mesa, Ruben A Journal: Lancet Issue: Volume 4:Issue 7(2017) Page Start: e317 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study. Issue 3 (March 2020) Authors: Kiladjian, Jean-Jacques; Zachee, Pierre; Hino, Masayuki; Pane, Fabrizio; Masszi, Tamas; Harrison, Claire N; Mesa, Ruben; Miller, Carole B; Passamonti, Francesco; Durrant, Simon; Griesshammer, Martin; Kirito, Keita; Besses, Carlos; Moiraghi, Beatriz; Rumi, Elisa; Rosti, Vittorio; Blau, Igor Wolfga... Journal: Lancet Issue: Volume 7:Issue 3(2020) Page Start: e226 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double‐blind, double‐dummy, symptom study (RELIEF). (8th November 2016) Authors: Mesa, Ruben; Vannucchi, Alessandro M.; Yacoub, Abdulraheem; Zachee, Pierre; Garg, Mamta; Lyons, Roger; Koschmieder, Steffen; Rinaldi, Ciro; Byrne, Jennifer; Hasan, Yasmin; Passamonti, Francesco; Verstovsek, Srdan; Hunter, Deborah; Jones, Mark M.; Zhen, Huiling; Habr, Dany; Martino, Bruno Journal: British journal of haematology Issue: Volume 176:Number 1(2017) Page Start: 76 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗